Bluejay Diagnostics (Bluejay Diagnostics) Growth Rank : 0 (As of May. 22, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bluejay Diagnostics Growth Rank?

Bluejay Diagnostics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Bluejay Diagnostics Growth Rank Related Terms

Thank you for viewing the detailed overview of Bluejay Diagnostics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Bluejay Diagnostics (Bluejay Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bluejay Diagnostics Inc (NAS:BJDX) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

360 Massachusetts Avenue, Suite 203, Acton, MA, USA, 01720

Website

https://www.bluejaydx.com

Bluejay Diagnostics Inc is a medical diagnostics company. It is engaged in developing, manufacturing, and marketing of clinical diagnostic products that improve the quality of medical diagnoses. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings. The company is a provider of rapid tests for infectious, inflammatory, and metabolic diseases by the Symphony platform.

Executives

Svetlana Dey	director, 10 percent owner	360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Indranil Dey	director, 10 percent owner, officer: Chief Technology Officer	360 MASSACHUSETTS AVENUW, SUITE 203, ACTON MA 0170
Frances P Scally	officer: CFO	66 MELANIE LANE, SYOSSET NY 11791
Jason Cook	officer: Chief Technology Officer	360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Kenneth R Fisher	officer: Chief Financial Officer	67 PROSPECT STREET, PEABODY MA 01960
Douglas Clark Wurth	director, 10 percent owner	4265 SAN FELIPE, SUITE 603, HOUSTON TX 77027
Gordon Winston Kinder	officer: Chief Financial Officer	360 MASSACHUSETTS AVENUE, SUITE 203, ACTON MA 01720
Gary G Gemignani	director	C/O IASO PHARMA INC., 12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Fred S Zeidman	director	109 NORTH POST OAK LANE, SUITE 422, HOUSTON TX 77024
Donald R Chase	director	39 TIMBER RIDGE RD., WEST SPRINGFIELD MA 01089